Alexion Pharmaceuticals (ALXN) PT Lowered to $147 at BMO Capital
Tweet Send to a Friend
BMO Capital analyst Matthew Luchini lowered the price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $147.00 (from $149.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
